At the news
? BULLISHIMPACT 6/10 PRESS-RELEASE filed Jun 29, 2026 at 07:30 ET
BrainsWay presented positive real-world data showing 83.5% of comorbid PTSD/MDD patients responded to Deep TMS with a 52% mean symptom reduction. However, the therapy is not yet FDA-cleared for PTSD, limiting immediate commercial impact. The data strengthens the clinical evidence base but does not change near-term revenue or regulatory status.
- 83.5% of 462 comorbid PTSD/MDD patients responded to Deep TMS (≥50% symptom reduction).
- Mean PTSD symptom reduction of 52% (PCL-5).
- 66.6% depression response rate, 27.3% remission rate, mean 50% PHQ-9 reduction.
- Deep TMS is not yet FDA-cleared for PTSD; results are from a retrospective, real-world study.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access